4 ms·

A lot of people believe Q-anon. This is such a shitty, drive by way of asserting something. Do you believe it? If so then make the case, but the way you've drop

A lot of people believe Q-anon. This is such a shitty, drive by way of asserting something. Do you believe it? If so then make the case, but the way you've dropped this steamy innuendo here without even taking a position on it yourself contributes less than nothing to the discussion.

wizzwizz4 6y ago
I haven't looked into it enough; I just remember Cory Doctorow talking about it and thought it was relevant. https://pluralistic.net/2021/04/13/public-interest-pharma/#gates-foundation https://pluralistic.net/2021/04/13/public-interest-pharma/#g... (citing https://khn.org/news/rather-than-give-away-its-covid-vaccine-oxford-makes-a-deal-with-drugmaker/ https://khn.org/news/rather-than-give-away-its-covid-vaccine...). The “a lot” came from the search results for “gates oxford covid patent” (I'd've expected people arguing against it if there was contention in opinion – this isn't the same as “it's fact”), though further investigation (the thing I didn't do; sorry) reveals that I only found two other articles: https://criticallegalthinking.com/2021/02/09/patent-capital-in-the-covid-19-pandemic-critical-intellectual-property-law/ https://criticallegalthinking.com/2021/02/09/patent-capital-... and https://criticallegalthinking.com/2021/02/09/patent-capital-in-the-covid-19-pandemic-critical-intellectual-property-law/; https://criticallegalthinking.com/2021/02/09/patent-capital-... the rest of the results are mirrors. You're right that it's a rubbish thing to write; I'll put more effort into comments in future.
- scotty79 6y ago
  How about this source: https://www.washingtonpost.com/washington-post-live/2021/02/10/transcript-washington-post-live-special-melinda-bill-gates/ https://www.washingtonpost.com/washington-post-live/2021/02/... MS. GATES: Well, we, along with many other partners, supported Oxford in saying what really needs to have happened there, they had incredible science, but they had never brought a vaccine to market. And so, they needed to partner with a pharmaceutical company who had expertise bringing a vaccine to market. And so, it was us and many partners that said that's a partnership that ought to happen. Ultimately, Oxford made that decision.

wizzwizz4 6y ago

I haven't looked into it enough; I just remember Cory Doctorow talking about it and thought it was relevant. https://pluralistic.net/2021/04/13/public-interest-pharma/#gates-foundation https://pluralistic.net/2021/04/13/public-interest-pharma/#g... (citing https://khn.org/news/rather-than-give-away-its-covid-vaccine-oxford-makes-a-deal-with-drugmaker/ https://khn.org/news/rather-than-give-away-its-covid-vaccine...). The “a lot” came from the search results for “gates oxford covid patent” (I'd've expected people arguing against it if there was contention in opinion – this isn't the same as “it's fact”), though further investigation (the thing I didn't do; sorry) reveals that I only found two other articles: https://criticallegalthinking.com/2021/02/09/patent-capital-in-the-covid-19-pandemic-critical-intellectual-property-law/ https://criticallegalthinking.com/2021/02/09/patent-capital-... and https://criticallegalthinking.com/2021/02/09/patent-capital-in-the-covid-19-pandemic-critical-intellectual-property-law/; https://criticallegalthinking.com/2021/02/09/patent-capital-... the rest of the results are mirrors. You're right that it's a rubbish thing to write; I'll put more effort into comments in future.

scotty79 6y ago
How about this source: https://www.washingtonpost.com/washington-post-live/2021/02/10/transcript-washington-post-live-special-melinda-bill-gates/ https://www.washingtonpost.com/washington-post-live/2021/02/... MS. GATES: Well, we, along with many other partners, supported Oxford in saying what really needs to have happened there, they had incredible science, but they had never brought a vaccine to market. And so, they needed to partner with a pharmaceutical company who had expertise bringing a vaccine to market. And so, it was us and many partners that said that's a partnership that ought to happen. Ultimately, Oxford made that decision.